Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: March 28, 2013
Last updated: May 18, 2015
Last verified: May 2015
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ). The data collected will be compared with the data from subjects without HZ in other HZ/su trials.

Condition Intervention Phase
Herpes Zoster
Biological: Herpes Zoster vaccine (GSK1437173A)
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Anti-gE humoral immunogenicity in terms of vaccine response. [ Time Frame: At Month 3 ] [ Designated as safety issue: No ]
  • Occurrence of solicited local and general symptoms. [ Time Frame: Within 7 days (Day 0-6) after each vaccination ] [ Designated as safety issue: No ]
    Occurrence, intensity and duration of each solicited local symptom. Occurrence, intensity, duration and relationship to vaccination of each solicited general symptom.

  • Occurrence of unsolicited adverse events. [ Time Frame: Within 30 days (Days 0-29) after each vaccination ] [ Designated as safety issue: No ]
  • Occurrence of Serious Adverse Events (SAEs). [ Time Frame: From first vaccination up to 30 days post last vaccination ] [ Designated as safety issue: No ]
  • Occurrence of AEs of specific interest. [ Time Frame: From first vaccination up to 30 days post last vaccination ] [ Designated as safety issue: No ]
    Occurrence of any potential Immune Mediated Diseases (pIMDs).

Secondary Outcome Measures:
  • Anti-gE humoral immunogenicity in each of the following age ranges: 50-59 YOA, 60-69 YOA and ≥ 70 YOA, in terms of antibody concentrations. [ Time Frame: At Month 0 and at Month 3 ] [ Designated as safety issue: No ]
  • Occurrence of SAEs. [ Time Frame: Starting after 30 days post last vaccination until study end (i.e. Month 14) ] [ Designated as safety issue: No ]
  • Occurrence of AEs of specific interest. [ Time Frame: Starting after 30 days post last vaccination until study end (i.e. Month 14) ] [ Designated as safety issue: No ]
    Occurrence of any pIMDs.

Enrollment: 96
Study Start Date: June 2013
Study Completion Date: November 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HZ Group
Subjects will receive 2 doses of the HZ/su vaccine at Month 0 and Month 2.
Biological: Herpes Zoster vaccine (GSK1437173A)
2 doses administered intramuscularly in deltoid region of non-dominant arm.
Other Name: HZ/su vaccine


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects with a physician-documented history of HZ.
  • Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • A male or female aged 50 years or older at the time of the first vaccination.
  • Written informed consent obtained from the subject.
  • Female subjects of non-childbearing potential may be enrolled in the study.

    • Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.
  • Female subjects of childbearing potential may be enrolled in the study, if the subject:

    • has practiced adequate contraception for 30 days prior to vaccination, and
    • has a negative pregnancy test on the day of vaccination, and
    • has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria:

  • Active Herpes Zoster infection (a case is considered no more active when all lesions have at least turned to crusts).
  • Use of any investigational or non-registered product other than the study vaccine/product within 30 days preceding the first dose of study vaccine/product, or planned use during the study period.
  • Chronic administration (defined as > 14 consecutive days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, a prednisone dose of <20 mg/day, or equivalent, is allowed. Inhaled, topical and intra-articular corticosteroids are allowed.
  • Administration of long-acting immune-modifying drugs within six months prior to the first vaccine dose or expected administration at any time during the study period.
  • Administration or planned administration of a live vaccine in the period starting 30 days before the first dose of study vaccine and ending 30 days after the last dose of study vaccine, or, administration or planned administration of a non-replicating vaccine within 8 days prior to or within 14 days after either dose of study vaccine.
  • Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational vaccine/product.
  • Previous vaccination against VZV or HZ and/or planned administration during the study of an HZ vaccine other than the study vaccine.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine/product.
  • Acute disease and/or fever at the time of enrolment.

    • Fever is defined as temperature ≥ 37.5°C /99.5°F for oral, axillary or tympanic route, or ≥ 38.0°C /100.4°F on rectal route. The preferred route for recording temperature in this study will be oral.
    • Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
  • Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
  • Any condition which, in the judgment of the investigator, would make intramuscular injection unsafe.
  • Pregnant or lactating female.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions before Month 4 (i.e. 2 months after the last dose of study vaccine).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01827839

Canada, British Columbia
GSK Investigational Site
Coquitlam, British Columbia, Canada, V3K 3P4
Canada, Quebec
GSK Investigational Site
Pointe-Claire, Quebec, Canada, H9R 4S3
Russian Federation
GSK Investigational Site
Barnaul, Russian Federation, 656056
GSK Investigational Site
Ekaterinburg, Russian Federation, 620137
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT01827839     History of Changes
Other Study ID Numbers: 116796  2012-003643-30 
Study First Received: March 28, 2013
Last Updated: May 18, 2015
Health Authority: United States: Food and Drug Administration
Russia: Ministry of Health of the Russian Federation
Canada: Health Canada

Keywords provided by GlaxoSmithKline:

Additional relevant MeSH terms:
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Immunologic Factors
Physiological Effects of Drugs processed this record on January 18, 2017